Skip to content
TrackPodcasts
businessJun 1, 201928:53pending

Anti-Biotic Resistance

The Bottom Line

About this episode

Antibiotic resistance is a global problem but there have been no new drugs produced since the 1980s. So who is to blame? The public's over-consumption or the current economic model for drug research and production? Evan Davis and guests discuss.

GUESTS

Seema Patel, Medical Director, Hospital Business, Pfizer, UK, Ireland and the Nordics

Lord Jim O'Neill, Chair Anti-Microbial Resistance Review (2016), Former Chief Economist, Goldman Sachs

Professor Colin Garner, Co Founder and Director, Antibiotic Research UK

Get every episode summarized

Each time The Bottom Line publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Anti-Biotic Resistance

The Bottom Line

0:00
28:53

More episodes

More from The Bottom Line

View all episodes →